United States Patent 5,844,099: What the Claims Actually Cover, Where the Landscape Tightens, and What Competitors Likely Do

US Patent 5,844,099 claims purified cytokine antagonists built from receptor extracellular domains that block cytokine function by forming a nonfunctional cytokine complex, with optional assembly using an immunoglobulin-derived interaction domain (including IgG Fc and IgG chain variants). The core concept is a “split-receptor extracellular architecture”: one antagonist component contains the extracellular domain of the cytokine receptor specificity (binding) subunit, and another contains the extracellular domain of the cytokine receptor signal-transducing (signaling) subunit, but both lack the receptor transmembrane and cytoplasmic domains. Dependent claims then specify IgG Fc or IgG heavy/light chain formats used to promote heterodimerization between the two extracellular components.

The claim set is broad on cytokine selection (multiple ILs plus GM-CSF, IFN-γ, and TGF-β) while narrow on the molecular construction (extracellular-only receptor fragments, and optionally immunoglobulin-based pairing).

What is claimed: a “purified” receptor-extracellular cytokine trap?

Claim 1 is the structural nucleus

Claim 1 requires:

A purified antagonist of a cytokine that:
- Includes (a): the extracellular domain of the cytokine receptor specificity-determining component, excluding the receptor transmembrane and cytoplasmic domains.
- Includes (b): the extracellular domain of the cytokine receptor signal transducing component, excluding the receptor transmembrane and cytoplasmic domains.
- Selects cytokine from:
- interleukin-1
- interleukin-2
- interleukin-3
- interleukin-4
- interleukin-5
- interleukin-15
- granulocyte macrophage colony stimulating factor (GM-CSF)
- gamma-interferon (interferon gamma, IFN-γ)
- Transforming Growth Factor-Beta (TGF-β)
- Binds cytokine to form a nonfunctional complex.

Claims 9–17 duplicate the concept by cytokine

Claims 9–17 are essentially product-by-target versions of the same architecture: each specifies a particular cytokine while retaining the “extracellular-only specificity component + extracellular-only signaling component” structure and the nonfunctional cytokine complex outcome.

Practical effect: this drafting reduces reliance on interpretive “component mapping” by anchoring the claims directly to named cytokines and their known receptor subunits.

How do the dependent claims narrow the assembly mechanism?

Claim 2 adds an Ig-derived coupling domain

Claim 2 requires that the antagonist further comprises:

an immunoglobulin derived domain capable of forming a complex between:
- the extracellular domain of the receptor specificity component, and
- the extracellular domain of the receptor signal transducing component.

This is not just an Fc tag. It is a claim element that the immunoglobulin-derived domain participates in complex formation between the two receptor extracellular parts.

Claims 3–8 specify which Ig format

Claim 3: IgG Fc domain
Claim 4: IgG heavy chain
Claim 5: heavy chain is C-gamma1 or C-gamma4
Claim 6: IgG light chain
Claims 7–8: light chain is kappa or lambda

Practical effect: the dependent claims map a family of Ig-based heterodimerization/association strategies onto the two extracellular receptor pieces.

What does “specificity determining” and “signal transducing” imply for claim scope?

Across cytokine receptors, many cytokine systems use:

a ligand-binding (specificity) subunit, and
a signaling (shared or partner) subunit that couples to downstream pathways.

Claim 1 does not require a particular receptor numbering system, but it does require that the antagonist includes extracellular-only fragments corresponding to:

the receptor specificity-determining component’s extracellular domain, and
the receptor signal-transducing component’s extracellular domain.

Scope pressure point: In a nontrivial receptor system, there can be multiple extracellular domains per subunit (or alternate isoforms). The claims still read broadly as long as the accused construct includes the extracellular domain(s) of both required receptor components while excluding transmembrane and cytoplasmic regions.

What is the functional requirement, and where does it create enforceability friction?

All asserted versions include:

“capable of binding [cytokine] to form a nonfunctional complex.”

Two enforceability angles usually matter:

Binding: Demonstrable binding is easier to test.
Nonfunctional complex: This is typically inferred from mechanism: if the receptor extracellular domains trap cytokine but do not trigger signaling (because transmembrane/cytoplasmic parts are absent), then the complex is “nonfunctional” by design.

That makes the claim likely to be read as a mechanistic outcome that flows from the missing intracellular regions, not as a separate assay-dependent requirement. Competitors can still argue about whether their complex is truly nonfunctional, but the architecture in claims 1 and 9–17 is built to make that argument difficult.

Cytokine coverage: a wide target set inside a narrow molecular pattern

Claim 1’s cytokine list is broad across pro-inflammatory cytokines, growth factors, and immune regulatory cytokines. Claims 9–17 then restate the architecture per cytokine.

Coverage table (as claimed)

Cytokine covered	Claim group	Claimed antagonist architecture (shared elements)
Interleukin-1	9	Extracellular-only receptor specificity subunit + extracellular-only signal-transducing subunit; cytokine trapped in nonfunctional complex
Interleukin-2	10	Same architecture
Interleukin-3	11	Same architecture
Interleukin-4	12	Same architecture
Interleukin-5	13	Same architecture
Interleukin-15	14	Same architecture
GM-CSF	15	Same architecture
IFN-γ	16	Same architecture
TGF-β	17	Same architecture

Patent landscape impact: why this claim style is designed to be hard to design around

This patent’s combination of elements is a classic enforcement posture:

Structural “receptor extracellular-only” limitation reduces direct substitution around transmembrane constructs.
Two-part extracellular receptor pairing blocks designs that use only the ligand-binding subunit.
Optional Ig coupling domain creates additional infringement paths for molecules that show Fc-mediated or Ig-chain-mediated pairing.

Design-around levers (typical in this area)

Even without citing specific competitors, the landscape’s predictable avoidance routes for receptor-trap antagonists fall into a few buckets:

Use only one receptor subunit extracellular domain
If a competitor builds a monovalent extracellular ligand-binding domain without including the extracellular portion of the signal-transducing partner, it weakens fit to claim 1’s requirement of both specificity and signal-transducing extracellular domains.
Include transmembrane or cytoplasmic components
Claim 1 explicitly excludes transmembrane and cytoplasmic domains from both receptor components. Any construct that violates those exclusions is outside the literal text.
Use non-Ig coupling architectures for the two extracellular parts
Claims 2–8 only apply when an immunoglobulin-derived domain is used to form the complex between the two extracellular pieces. A competitor that pairs the two extracellular domains using non-Ig scaffolds may still fall under claim 1 but avoid dependent claim coverage.
Use a different “nonfunctional complex” mechanism
If a competitor’s molecule binds cytokine but does not form the claimed nonfunctional receptor-like complex, they may attack the functional language. In practice, many receptor-trap antagonists aim for the same “no signaling” outcome, so this is often not a clean design-around.

Bottom line: the core infringement zone is claim 1’s “two extracellular receptor components” requirement. Dependent coverage expands possible architectures using Ig-based pairing.

Critical claim audit: likely indefiniteness and construction issues

This matters because claim interpretation can decide whether the patent blocks a competitor’s entire program or only a narrow form.

1) “Extracellular domain but not transmembrane and cytoplasmic domains”

This language is relatively clean because it defines the omission of TM and cytoplasmic regions.

Potential issues:

What exactly constitutes the “extracellular domain” can vary across receptor annotation databases and isoforms.
If the competitor includes additional membrane-proximal residues beyond a defined extracellular boundary, it can create factual disputes on whether “transmembrane” is included.

2) “Specificity determining component” and “signal transducing component”

These labels can be operational rather than literal. For some receptors:

the specificity-binding subunit is clear (e.g., ligand-binding chain),
the signal transduction partner is also clear, but in certain cytokine receptor families:
shared signaling subunits exist,
alternate alpha chains exist,
and sometimes multiple arrangements are used.

Claim 9–17 mitigate interpretive ambiguity by anchoring the cytokine to named receptor components, but claim scope still depends on how the patent defines the component mapping for each cytokine.

3) “Immunoglobulin derived domain capable of forming a complex”

This is a functional pairing limitation. Courts can require a direct relationship between:

the Ig-derived domain used, and
the actual physical complex formation between the two receptor extracellular domains.

If a competitor uses Ig sequences as a fusion partner for expression/half-life but does not use it as the complex-forming interface between the two receptor extracellular components, they may argue non-infringement of claims 2–8 while still potentially infringing claim 1.

What the claims signal about the invention’s commercial intent

The patent is structured to capture:

receptor extracellular fragment antagonists broadly across multiple cytokines (claims 1, 9–17), and
Ig-based dimerization formats (claims 2–8) that are common in biologics for stability and manufacturability.

That combination suggests an enforcement focus on a class of “receptor-trap” biologics rather than on one cytokine candidate.

Risk map: which claim elements are “must hit” vs “optional”

Core must-hit elements (claim 1)

A product is most at risk of hitting claim 1 if it includes all of:

purified antagonist
includes extracellular-only receptor specificity subunit
includes extracellular-only receptor signal transducing subunit
cytokine binding forming a nonfunctional complex
cytokine is one of the listed targets

Optional add-ons (claims 2–8)

To hit dependent claims, a product must also include:

an Ig-derived domain that forms the complex between the two receptor extracellular components
- Fc, IgG heavy chain (C-gamma1/C-gamma4), or IgG light chain (kappa or lambda)

Practical point: A competitor that avoids Ig coupling might still face claim 1 risk.

Key Takeaways

US 5,844,099 claims a class of cytokine antagonists built from two receptor extracellular-only fragments: one from the specificity component and one from the signal-transducing component, with both lacking TM and cytoplasmic domains.
The invention is target-broad across nine cytokines (IL-1, IL-2, IL-3, IL-4, IL-5, IL-15, GM-CSF, IFN-γ, TGF-β) while construction-specific in requiring the two-part receptor extracellular pairing.
Dependent claims expand enforceability for molecules that use an Ig-derived domain (IgG Fc, IgG heavy chain with C-gamma1/C-gamma4, or IgG kappa/lambda light chain) as the complex-forming mechanism between the two extracellular receptor parts.
The main design-around pressure points are: missing one receptor component’s extracellular domain, including TM/cytoplasmic regions, and avoiding Ig-derived complex-forming interfaces (though claim 1 may still apply without Ig).

FAQs

Does claim 1 cover Fc-fusion receptor traps even if they are not designed to trigger signaling?
Yes, claim 1 does not require an Fc element. It requires extracellular-only receptor specificity and signal-transducing components that bind cytokine to form a nonfunctional complex.
Which element is the biggest barrier to design-around?
The requirement to include extracellular domains from both the receptor specificity component and the receptor signal-transducing component (while excluding TM/cytoplasmic domains).
Do claims 9–17 add new technical features beyond claim 1?
No new architecture is introduced; they restate the same extracellular two-component antagonist concept for each named cytokine.
How do claims 2–8 change infringement risk?
They add an Ig-derived domain that must form the complex between the two extracellular receptor components. Avoiding Ig coupling may reduce risk of dependent claim infringement while leaving claim 1 risk intact.
Is the “nonfunctional complex” requirement likely to be interpreted mechanistically or as an assay limitation?
It is framed as a capability of forming a nonfunctional complex. Given the explicit exclusion of TM and cytoplasmic domains, the nonfunctionality is tightly linked to the receptor-trap architecture.

References

[1] U.S. Patent 5,844,099.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	February 27, 2008	⤷ Start Trial	2015-11-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	948242	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9511303	⤷ Start Trial
United States of America	5470952	⤷ Start Trial
Portugal	726954	⤷ Start Trial
Japan	H09504030	⤷ Start Trial
Japan	3961562	⤷ Start Trial
Hong Kong	1008346	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 5,844,099

Summary for Patent: 5,844,099